Community-viable screening for ASD in 9-month-old infants using quantitative eye-tracking assays of social visual engagement

使用社交视觉参与的定量眼动追踪分析对 9 个月大的婴儿进行社区可行的 ASD 筛查

• 批准号: 10254287
• 负责人: Warren Jones
• 金额: $ 75.98万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-16 至 2025-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10254287
• 关键词: Affect; Age; Age-Months; Agreement; Biological Assay; Blinded; Child; Childhood; Clinical; Communities; Data; Data Analytics; Data Collection; Development; Developmental Delay Disorders; Developmental Diagnostic; Devices; Diagnosis; Diagnostic; Diagnostic Sensitivity; Dimensions; Double-Blind Method; Early Intervention; Effectiveness; Enrollment; Evaluation; General Population; Goals; Gold; Improve Access; Individual; Infant; Investigation; Language; Learning; Measurement; Measures; Methodology; Methods; Modeling; National Institute of Mental Health; Neuronal Plasticity; Outcome; Performance; Physicians; Population; Predictive Value; Primary Health Care; Procedures; Reference Standards; Research Design; Risk; Risk Assessment; Sampling; Screening procedure; Sensitivity and Specificity; Series; Severities; Specific qualifier value; Specificity; Standardization; Symptoms; Technology; Testing; Time; Translations; Validation; Visual; Well Child Visits; autism spectrum disorder; autistic; base; cognitive ability; cognitive skill; cohort; cost effective; design; diagnosis standard; disability; efficacy testing; experience; indexing; infancy; instrument; population based; recruit; response; screening; secondary analysis; service intervention; social; tool; visual tracking

PROJECT SUMMARY This project is in response to NIMH RFA-MH-19-120 calling for the development and validation of new screening methods for autism spectrum disorder (ASD) that can be used in infancy (0-12 months of age). We will deploy a cost-effective, high-throughput methodology utilizing performance-based, objective, and highly quantitative eye- tracking assays of social visual engagement—the way in which infants visually explore, engage, and ultimately learn from and adapt to their surrounding world—collected on a standalone, mobile eye-tracking data collection device, created in our lab (the Marcus Autism Center Investigational Device, MAC-ID). We will collect eye- tracking data from a population-based sample of N=2,000 9-month-old infants recruited consecutively in primary care practices at the time of their 9-month well-child visits. These infants will be followed longitudinally from 9 until 26 months for completion of a series of sequential screening and clinical ascertainment procedures designed to maximize sensitivity and achieve clinician-best-estimate diagnostic assignments of ASD vs. non- ASD and Affected [including ASD and non-ASD developmental delays] vs. Unaffected. We will measure the accuracy of eye-tracking-based screening at the age of 9 months relative to clinician best estimate diagnosis at 24 months (primary analysis), and we will measure dimensional agreement between eye-tracking assays at 9 months relative to outcome levels of social disability, verbal ability, and nonverbal cognitive ability (secondary analyses). Our overarching goal is to develop high-quality, objective, performance-based tools that can function as an effective and community-viable means of screening for ASD and other actionable developmental delays in infancy, to ultimately facilitate improved access to and benefit from early intervention.

项目摘要 该项目是为了响应NIMH RFA-MH-19-120要求开发和验证新的筛选方法， 自闭症谱系障碍（ASD）的方法，可以在婴儿期（0-12个月大）使用。我们将部署一个 成本效益高，高通量的方法，利用基于性能，客观，和高度定量的眼睛， 社会视觉认知的跟踪分析--婴儿视觉探索、参与并最终 从周围世界中学习并适应--通过独立的移动的眼动跟踪数据收集系统收集 设备，在我们的实验室创建（马库斯自闭症中心研究设备，MAC-ID）。我们会收集眼睛- 跟踪数据来自一个基于人群的样本，N=2,000个9个月大的婴儿连续招募的初级 在他们9个月的健康儿童访问时进行护理。这些婴儿将从9岁开始纵向随访， 直至26个月，以完成一系列序贯筛选和临床确定程序 旨在最大限度地提高灵敏度，并实现ASD与非ASD的临床医生最佳估计诊断分配。 ASD和受影响[包括ASD和非ASD发育迟缓]与未受影响。我们将测量 9个月时基于眼动追踪的筛查相对于临床医生最佳估计诊断的准确性 24个月（主要分析），我们将在9个月时测量眼动追踪试验之间的尺寸一致性 月相对于社会残疾，语言能力和非语言认知能力（次要）的结果水平 分析）。我们的首要目标是开发高质量、客观、基于性能的工具， 作为筛查ASD和其他可行的发育迟缓的有效和社区可行的手段 在婴儿期，最终促进更好地获得早期干预并从中受益。